Literature DB >> 415987

Inhibition of allergic reactions by cromoglycate and by a new antiallergy drug U-42,585E. II. Activity in primates against aerosolized Ascaris suum antigen.

H G Johnson, C A VanHout, J B Wright.   

Abstract

Immediate type hypersensitivity to Ascaris antigen in Rhesus reactor monkeys was used to assess the pharmacologic profile of cromolyn Na (DSCG) and a new inhibitor of IgE-mediated lung function changes (U-42,585E). Two parameters used to measure lung function, respiratory rate increase and tidal volume decrease, were significantly altered in a dose-related fashion by U-42,585E when the latter was administered either by the intravenous, intrabronchial, or the oral route. Oral activity of U-42,585E was demonstrated with doses as low as 5 mg/kg in Ascaris reactor primates.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 415987     DOI: 10.1159/000232062

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  6 in total

1.  The effect of lodoxamide ethyl [diethyl N,N'-(2-chloro-5-cyano-m-phenylene)dioxamate] on in vivo anaphylactic reactions.

Authors:  H G Johnson; R L Griffin; J B Wright
Journal:  Agents Actions       Date:  1979-08

2.  Alternative modes of action of sodium cromoglycate.

Authors:  I M Richards; M Dixon; D M Jackson; K Vendy
Journal:  Agents Actions       Date:  1986-06

3.  Inhibition of oxidative enzymes by anti-allergy drugs.

Authors:  G J White
Journal:  Agents Actions       Date:  1981-11

4.  Inhalation challenge with specific grass pollen antigens in asthmatics and the effect of lodoxamide tromethamine.

Authors:  R W Parrish; B H Davies
Journal:  Thorax       Date:  1983-06       Impact factor: 9.139

5.  Ascaris-induced bronchoconstriction in primates experimentally infected with Ascaris suum ova.

Authors:  I M Richards; R P Eady; D M Jackson; T S Orr; D I Pritchard; K Vendy; E Wells
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

6.  The characterization of lodoxamide, a very active inhibitor of mediator release, in animal and human models of asthma.

Authors:  H G Johnson; A Q Sheridan
Journal:  Agents Actions       Date:  1986-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.